Cytokinetics Inc (NASDAQ: CYTK) stock closed at $54.58 on 6/5/24 after a major increase of 12.7%. Moreover, trading volume in this advance was exceptionally high at 303% of normal. The stock has been exceptionally strong relative to the market over the last nine months and has risen 13.2% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be below the cost of capital, CYTK is expected to be a major Value Eraser.
Cytokinetics is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment